{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:47:10Z","timestamp":1790066830861,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T00:00:00Z","timestamp":1472169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008469","name":"Canadian Urological Oncology Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s10637-016-0386-z","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T06:38:42Z","timestamp":1472193522000},"page":"771-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)"],"prefix":"10.1007","volume":"34","author":[{"given":"Sunil","family":"Parimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Eliasziw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Ruether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J.","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"key":"386_CR1","first-page":"1502","volume":"351","author":"IF Tannock","year":"2014","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. (2014) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Eng. J Med 351:1502\u20131512","journal-title":"J Med"},{"key":"386_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 368:138\u2013148","journal-title":"New Engl J Med"},{"issue":"5","key":"386_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med 371(5):424\u2013433","journal-title":"New Engl J Med"},{"key":"386_CR4","doi-asserted-by":"crossref","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. NEJM 2013 369(3):213\u201323","DOI":"10.1056\/NEJMoa1213755"},{"issue":"9747","key":"386_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguoglu M, Hansen S, Machiels J, Kocak I, et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147\u20131154","journal-title":"Lancet"},{"key":"386_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. (2004) Docetaxel and Estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 351:1513\u20131520","journal-title":"New Engl J Med"},{"issue":"1","key":"386_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/pcan.2015.53","volume":"19","author":"BA Teply","year":"2016","unstructured":"Teply BA, Luber B, Denmeade SR, et al. (2016) The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 19(1):72\u201378","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"15","key":"386_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","volume":"33","author":"NE Ready","year":"2015","unstructured":"Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, et al. (2015) Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (alliance. J Clin Oncol 33(15):1660\u20131665","journal-title":"J Clin Oncol"},{"key":"386_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Capuzzo","year":"2010","unstructured":"Capuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomized, placebo-controlled phase 3 study. Lancet Oncol 11:521\u2013529","journal-title":"Lancet Oncol"},{"issue":"1","key":"386_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 14(1):29\u201337.23","journal-title":"Lancet Oncol"},{"key":"386_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Rixe O, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356:115\u2013124","journal-title":"New Engl J Med"},{"key":"386_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356:125\u2013134","journal-title":"New Engl J Med"},{"issue":"2","key":"386_CR13","first-page":"401","volume":"143","author":"N Weidner","year":"1993","unstructured":"Weidner N, Carrol PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastases in invasive prostate carcinoma. Am J Pathol 143(2):401\u2013409","journal-title":"Am J Pathol"},{"issue":"3","key":"386_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0090-4295(99)00167-3","volume":"54","author":"JL Duque","year":"1999","unstructured":"Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54(3):523\u2013527","journal-title":"Urology"},{"key":"386_CR15","first-page":"1932","volume":"7","author":"DJ George","year":"2001","unstructured":"George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res 7:1932\u20131936.23","journal-title":"Clin Cancer Res"},{"issue":"22","key":"386_CR16","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Oudard S, et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584\u20133590","journal-title":"J Clin Oncol"},{"key":"386_CR17","doi-asserted-by":"crossref","unstructured":"Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, et al. (2009) Final analysis of a phase II trial using sorafenib for metastatic castration resistant prostate cancer. BJU Int:103\u20131636","DOI":"10.1111\/j.1464-410X.2008.08327.x"},{"issue":"4","key":"386_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","volume":"31","author":"DC Smith","year":"2013","unstructured":"Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4):412","journal-title":"J Clin Oncol"},{"issue":"7","key":"386_CR19","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. (2008) Design and end point of clinical trials of patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148\u20131159","journal-title":"J Clin Oncol"},{"key":"386_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1. Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"386_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/annonc\/mdp111","volume":"20","author":"MD Michaelson","year":"2009","unstructured":"Michaelson MD, Regan MM, WK O, Kaufman DS, Olivier K, Michaelson SZ, et al. (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913\u2013920","journal-title":"Ann Oncol"},{"issue":"11","key":"386_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2967\/jnumed.112.105007","volume":"53","author":"PJ Saylor","year":"2012","unstructured":"Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD (2012) Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med 53(11):1670\u20131675","journal-title":"J Nucl Med"},{"issue":"2","key":"386_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","volume":"32","author":"MD Michaelson","year":"2014","unstructured":"Michaelson MD, Oudard S, Ou Y, Sengelov L, Saad F, Houede N, et al. (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32(2):76\u201382","journal-title":"J Clin Oncol"},{"key":"386_CR24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, et al. (2012) Randomized, double-blind, placebo controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534\u20131540","journal-title":"J Clin Oncol"},{"key":"386_CR25","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S, et al. (2013) Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14:760\u2013768","journal-title":"Lancet Oncol"},{"key":"386_CR26","doi-asserted-by":"crossref","unstructured":"Chi KN, Ellar SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, et al. (2008) A phase II study of sorafenib inpatients with chemo-na\u00efve castration resistant prostate cancer. Ann Oncol:19\u2013746","DOI":"10.1093\/annonc\/mdm554"},{"issue":"2","key":"386_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clgc.2014.06.001","volume":"13","author":"SS Sridhar","year":"2015","unstructured":"Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J, Wang L, Harris P, Chi KNA (2015) Phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 13(2):124\u2013129","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"386_CR28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s10637-014-0091-8","volume":"32","author":"AA Azad","year":"2014","unstructured":"Azad AA, Beardsley EK, Hotte SJ, Ellard SL, Klotz L, Chin J, Kollmannsberger C, Mukherjee SD, Chi KNA (2014) Randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naive castration-resistant prostate cancer. Investig New Drugs 32(4):746\u2013752","journal-title":"Investig New Drugs"},{"key":"386_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S, Karlsson CT (2013) Flechon Aude, Skoneczna I, et al. aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomized trial. Lancet Oncol 14:760\u2013768","journal-title":"Lancet Oncol"},{"key":"386_CR30","unstructured":"Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. 2009 Genitourinary Cancer Symposium, February 26\u201328, 2009, Orlando FL"},{"issue":"suppl","key":"386_CR31","doi-asserted-by":"crossref","first-page":"abstr 4511","DOI":"10.1200\/jco.2012.30.15_suppl.4511","volume":"30","author":"DI Quinn","year":"2012","unstructured":"Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, et al. (2012) SWOG S0421: phase III study of docetaxel and atrasentan versus docetaxel and placebo for men with advanced castrate resistant prostate cancer. Proc Am Soc Clin Oncol 30(suppl):abstr 4511","journal-title":"Proc Am Soc Clin Oncol"},{"key":"386_CR32","unstructured":"Fizazi K, Higano C, Nelson J, Gleave M, Miller K, Morris T, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with metastatic castrationresistant prostate cancer. J Clin Oncol (in press)"},{"key":"386_CR33","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534\u20131540","journal-title":"J Clin Oncol"},{"issue":"4","key":"386_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","volume":"16","author":"DP Petrylak","year":"2015","unstructured":"Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, et al. (2015) Docetaxel and prednisone with or without lenalidomide in chemotherapy-na\u00efve patietns with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind pacebo-controlled phase 3 trial. Lancet Oncol 16(4):417\u2013425","journal-title":"Lancet Oncol"},{"key":"386_CR35","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","volume":"14","author":"JC Araujo","year":"2013","unstructured":"Araujo JC, Trudel GC, Saad F, Armstrong AJ, EY Y, Bellmunt J, et al. (2013) Overall survival (OS) and safety of dasatinib\/docetaxel versus docetaxel in patients with metastatic castration resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. Lancet Oncol 14:1307\u20131316","journal-title":"Lancet Oncol"},{"key":"386_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","volume":"13","author":"R Melzack","year":"1975","unstructured":"Melzack R (1975) The pain questionnaire: major properties and scoring methods. Pain 13:277\u2013299","journal-title":"Pain"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0386-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0386-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:59:44Z","timestamp":1678510784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0386-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0386-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]},"assertion":[{"value":"15 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Eigl has received an honorarium from Pfizer within the last 2\u00a0years. Dr. Sunil Parimi declares that he has no conflict of interest. Ms. Misha Eliasziw declares that she has no conflict of interest. Dr. Scott North declares that he has no conflict of interest. Dr. Marc Trudeau declares that he has no conflict of interest. Dr. Eric Winquist declares that he has no conflict of interest. Dr. Kim N. Chi declares that he has no conflict of interest. Dr. Dean Ruether declares that he has no conflict of interest. Dr. Tina Cheng declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This project was supported through an investigator initiated research grant from Pfizer and conducted with the support of the Canadian Uro-Oncology Group (CUOG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}